# Preliminary Results of Surgical Treatment for Enchondroma Using a Novel Bioactive and Osseoconductive HAP/β–Glucan Bone Substitute FlexiOss®—Case Series

## TL;DR

This case series explores the use of a new bone substitute in treating enchondroma, showing promising functional outcomes and bone healing.

## Contribution

The study introduces a novel bioactive and osseoconductive HAP/β–glucan bone substitute for enchondroma treatment.

## Key findings

- All patients achieved very good functional results with MSTS scores of 27–30.
- Bone remodeling was mostly favorable, with six cases scoring I and two scoring II on the modified Neer scale.
- Two patients experienced minor complications with serous wound discharge.

## Abstract

Background/Objectives: In the surgical treatment of benign bone tumors, bone substitutes are widely used. However, each of them has its advantages and disadvantages. We decided to study the novel bioactive and osseoconductive HAP/β–glucan bone substitute. Methods: We qualified eight patients with enchondroma of the lower limbs for this study, who underwent marginal resection of the lesion with the use of a bone substitute—FlexiOss®. During the 12-month follow-up, a series of X-rays and bone scintigraphy were performed. Bone remodeling was assessed using the modified Neer scale (MNS), while functional results were assessed using the MSTS scale. Results: Very good functional results were noted in all patients—MSTS = 27–30. In the MNS, Score I was recorded in six cases, and Score II was recorded in two cases. Among the complications in the two patients, a clear serous discharge from the wound was observed. Conclusions: The use of the new HAP/β–glucan composite in the treatment of enchondroma initially shows good treatment results.